Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.20 (16.667%)
Open: 1.30
High: 1.30
Low: 1.30
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Galantas Gold closes placement; Kropz makes draw down

Tue, 28th Mar 2023 16:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Kropz PLC - South Africa-focused phosphate producer and developer - Make second drawdown on loan, for ZAR90 million. On March 14, it entered a new bridge loan facilities of ZAR285 million with major shareholder ARC Fund, in order to meet immediate cash requirements at Kropz Elandsfontein (Pty) Ltd. The company noted that the first draw down on the loan was made on this date, for ZAR25 million.

----------

Contango Holdings PLC - natural resource development company with operations in Africa - Says wash plant construction at its Lubu coking coal project in Zimbabwe is now complete ahead of commissioning and the production of coking coal. Refurbishment of the screen, used to sort the coking coal prior to it being fed through the wash plant, is also near completion in Harare and is expected to be delivered to site in early April, with installation immediately thereafter. Power to the wash plant and other processing facilities will be connected at the same time, expected to be mid-April. The company intends to undertake grade control drilling for approximately 8 days in early April to help ensure the subsequent extraction and processing of the coking coal is optimised. "We have continued to make excellent progress at site as we prepare for imminent first coking coal production and sales. Next month we intend to activate our wash plant and commence the processing of coal ahead of subsequent sales under our existing offtake agreements," Chief Executive Carl Esprey says.

----------

Galantas Gold Corp - Northern Ireland-focused gold producer - Closes its CAD3.0 million non-brokered private placement of 8.2 million shares priced at CAD0.36 per unit. Each placement share comes with a warrant to buy another share at CAD0.55 over the next five years. Says the offering was oversubscribed. At the start of March, Glantas announced plans of a non-brokered private placement of 5.6 million shares to raise up to CAD2.0 million. The company plans to use the proceeds for exploration including follow-up drilling targeting the high-grade dilation zones to depth at the Joshua Vein, the recently identified Kerr Vein target, development at Galantas' gold project in Northern Ireland as well as exploration at the recently announced gold-rich volcanogenic massive sulphide project in Scotland.

----------

Physiomics PLC - London-based oncology consultancy, which uses mathematical models to support the development of cancer treatment regimens and personalised medicine solutions - Signs an agreement with Beyond Blood Diagnostics Ltd to analyse data generated during testing of its diagnostic platform using Physiomics' personalised dosing software. Beyond Blood is a seed-stage spin out from Imperial College London, which is developing a patented flow cytometry device to measure blood cell counts (such as neutrophils) in very small blood volumes, Physiomics says. "A diagnostic device that enables the collection of neutrophil counts in a home setting could address the challenge faced by patients that may be reluctant to travel into hospital for additional blood tests currently required by Physiomics' software in some care settings," it explains.

----------

Union Jack Oil PLC - oil and gas company with a focus on onshore production, development, exploration and investment opportunities within the UK hydrocarbon sector - Declares an interim dividend of 0.3p per share. Says the financial position of Union Jack during 2022 and the first quarter of 2023 has been "transformational" and therefore it decided to make a further distribution to shareholders. Also implements a share buyback programme, funded by the company's existing cash. As of , the company has purchased 2.8 million shares in open market transactions it says. The company has placed the ordinary shares purchased into treasury. Executive Chair David Bramhill comments: "Union Jack's financial position has been transformational and the company has a robust balance sheet, a fully funded and active work programme for its principal projects and has no borrowings."

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 Nov 2023 08:14

Physiomics receives Innovate UK funding grant

(Sharecast News) - Computational biology firm Physiomics said on Friday that it had been awarded a grant by Innovate UK and the Office for Life Sciences as part of the UK Government's Advancing Precision Medicine programme.

Read more
28 Sep 2023 12:12

Physiomics shares drop as annual loss widens; revenue falls

(Alliance News) - Physiomics PLC on Thursday kept its outlook upbeat, despite reporting a drop in revenue in what it called a "difficult year."

Read more
28 Sep 2023 11:47

LONDON MARKET MIDDAY: Stocks stay downbeat; Digital 9 plunges 32%

(Alliance News) - Stock prices in London were lower at midday on Thursday as elevated oil prices added fuel to inflationary fears and supported the higher for longer narrative around global interest rates.

Read more
28 Sep 2023 10:44

AIM WINNERS & LOSERS: Bradda shares surge on updated resource estimate

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Sep 2023 11:21

Physiomics brings in chief operating officer; shares soar

(Alliance News) - Physiomics PLC on Monday named Peter Sargent as its new chief operating officer.

Read more
4 Sep 2023 10:27

AIM WINNERS & LOSERS: Physiomics brings in COO; Ergomed receives bid

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Aug 2023 16:50

LONDON MARKET CLOSE: FTSE 100 down amid stubborn US inflation

(Alliance News) - Stock prices in London closed mixed on Thursday, after news that a key US inflation reading came in in line with market expectations.

Read more
31 Aug 2023 13:51

UPDATE: Physiomics wins new deal following Merck contract extension

(Alliance News) - Physiomics PLC on Thursday said it won its first contract with an unnamed "UK-based biotech client".

Read more
31 Aug 2023 10:41

IN BRIEF: Physiomics to extend anti-cancer regimen work with Merck

Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Has been awarded a further contract by existing client Merck KGaA involving pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage and repair agents. Follows on previous Merck-commissioned projects. Expects the contract award to be completed over the next three months.

Read more
24 Aug 2023 11:06

ValiRx interim loss widens as costs increase; hails Inaphaea progress

(Alliance News) - ValiRx PLC on Thursday reported an increased half-year loss amid higher costs, as it continued to focus on building its science-focused portfolio.

Read more
8 Aug 2023 15:49

Physiomics inks contract extension with Numab Therapeutics

(Sharecast News) - Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.

Read more
8 Aug 2023 10:48

IN BRIEF: Physiomics inks further contract with Numab Therapeutics

Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Says it has been awarded a further contract by its existing client, Numab Therapeutics. Numab Therapeutics is a Switzerland-based biotechnology firm. The project involves pharmacokinetic-pharmacodynamic modelling in support of one of Numab's clinical programs and follows on from earlier work conducted by Physiomics on the same asset. The project will span two years of the clinical program.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
27 Jun 2023 10:49

Physiomics completes GBP335,000 fundraise; announces new retail offer

(Alliance News) - Physiomics PLC on Tuesday said it had completed a fundraise, conditional on admission, of GBP335,000 through a placing with Hybridan LLP, and announced a retail offer from Winterflood retail access platform to raise a maximum of GPB150,000.

Read more
27 Jun 2023 10:17

AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.